

Appendix VI
EXTRAORDINARY INFORMATION DISCLOSURE
(Issued with the Decision No. 21/QĐ-SGDVN on December 21, 2021 of the CEO of Vietnam Exchange on the Information Disclosure Regulation of Vietnam Exchange)

**AGIMEXPHARM PHARMACEUTICAL
JOINT STOCK COMPANY**

THE SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

No.: 11/CBTT-AGP

An Giang, April 14, 2025

EXTRAORDINARY INFORMATION DISCLOSURE

To: Hanoi Stock Exchange

1. Name of organization: AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY
 - Stock code: AGP
 - Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province
 - Tel: 02963.856964
 - E-mail: agp@agimexpharm.com
2. Contents of disclosure: Announcement on share issuance for 2024 dividend payment.
3. This information was published on the company's website on April 14, 2025, as in the link <https://agimexpharm.com/shareholder/>

We hereby certify that the information provided is true and correct and we bear the full responsibility to the law.

Attached documents:

- Announcement No. 01/TB-AGP.

Legal representative
General Director

Phar. Nguyen Van Kha

**ANNOUNCEMENT
ON SHARE ISSUANCE FOR 2024 DIVIDEND PAYMENT**

I. Introduction to the issuing organization

1. Issuer name: Agimexpharm Pharmaceutical Joint Stock Company
2. Abbreviated name: AGIMEXPHARM
3. Head office address: No. 27, Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province, Vietnam
4. Phone: (0296) 385 6961 - 385 6964 Fax: (0296) 385 7301
Website: www.agimexpharm.com
5. Charter capital: VND 231,439,410,000
6. Securities code: AGP
7. Payment account: Vietnam Joint Stock Commercial Bank for Industry and Trade – An Giang Branch
Account number: 110000016076
8. Enterprise registration certificate: Certificate No.: 1600699279, issued by the Department of Planning and Investment of An Giang Province, first issued on June 3, 2004, 18th amendment on May 22, 2024.
 - Main business activities: Manufacturing pharmaceuticals, medicinal chemicals and herbal products. Trading in optical equipment, medical devices, dental equipment and hospital equipment. Trading in pharmaceuticals and drugs. Trading in nutritional food products. Manufacturing and trading cosmetics. Trading in raw materials and chemical substances for pharmaceutical production. Trading in vaccines and medical biological products. Producing bottled and packaged drinking water (ensuring compliance with food safety regulations). Manufacturing functional foods and herbal essential oils. Producing and trading in food, nutritional food and functional food - Industry code: 2100
 - Primary products/services: Pharmaceutical products and drugs
9. Business license: License for pharmaceutical business No. 4526/DKKDD-AG, 3rd re-issuance No. 4133/DKKDD-AG, issued on December 20, 2023.

II. Plan for share issuance for dividend payment

1. Securities name: Shares of Agimexpharm Pharmaceutical Joint Stock Company
2. Type of securities: Common shares
3. Total number of issued shares: 23,143,941 shares
4. Total number of outstanding shares: 23,143,941 shares
5. Total number of treasury shares: 0 shares
6. Estimated number of shares to be issued: 2,314,394 shares



7. Total value of issuance at par value: VND 23,143,940,000 (In words: Twenty-three billion one hundred forty-three million nine hundred forty thousand dong)
8. Issuance ratio: 10:01. Shareholders holding 1 share will receive 1 right. Every 10 rights will be entitled to receive 1 new share.
9. Source of issuance funds: Retained earnings after tax as of December 31, 2024, based on the audited financial statements for the year 2024 of Agimexpharm Pharmaceutical Joint Stock Company.
10. Handling of fractional shares: The number of additional shares issued to each shareholder will be rounded down to the nearest whole number. Any fractional shares (if any) will be canceled.
*For example: Shareholder A owns 128 shares on the record date. With an entitlement ratio of 10:01, Shareholder A will receive $(128/10 * 01) = 12.80$ new shares. Based on the rounding rule, Shareholder A will receive 12 new shares. The fractional 0.80 share will be canceled.*
The positive difference between the total expected issuance value of dividend shares (calculated at the par value of VND 10,000 per share) and the total actual value of distributed shares (calculated at the par value of VND 10,000 per share) will be allocated to the Company's Development Investment Fund.
11. Record date for rights allocation: May 6, 2025.

AGIMEXPHARM PHARMACEUTICAL JSC

GENERAL DIRECTOR



PHẠM NGUYỄN VĂN KHA

